Jump to content

Digoxin immune fab

From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by KDS4444 (talk | contribs) at 01:38, 3 December 2016 (→‎Contraindications: links). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Digoxin immune fab
Clinical data
AHFS/Drugs.comConsumer Drug Information
Routes of
administration
IV infusion, injection
ATC code
Pharmacokinetic data
Elimination half-life15 hours for DigiFab, 23 hours for Digibind
ExcretionRenal
Identifiers
  • Anti-digoxin antibody fragment
DrugBank
ChemSpider
  • none
ChEMBL
Chemical and physical data
FormulaC6394H9908N1698O2011S58
Molar mass144602.257 g/mol g·mol−1
 ☒NcheckY (what is this?)  (verify)

Digoxin immune fab or Digoxin-specific antibody is an antidote for overdose of digoxin.[1] It is made from immunoglobulin fragments from sheep that have already been immunized with a digoxin derivative, digoxindicarboxymethoxylamine. Its brand names include Digibind ( GlaxoSmithKline) and DigiFab (BTG plc).

Digoxin immune fab used to treat digoxin toxicity

Pharmacology

It works by binding to the digoxin, rendering it unable to bind to its action sites on target cells. The complexes accumulate in the blood and are expelled by the kidney.

Indications

  1. Hemodynamically unstable arrhythmia
  2. End organ damage
  3. digoxin level > 4 ng/ml if chronic ingestion
  4. digoxin level > 10 ng/ml if acute ingestion
  5. potassium > 5 mEq/L and symptomatic [2]

[3]

Contraindications

Avoid use in hypokalemia as this drug, while reversing the effects of digitalis, will further reduce serum potassium levels and could precipitate dangerous and even fatal cardiac arrhythmias.

The patient must be closely monitored for anaphylactic shock, and anyone allergic to sheep protein, papain, bromelain, or papaya extracts (papain is used to cleave the antibody into Fab and Fc fragments) should not use ovine digoxin immune fab. Because it is relatively new, no drug interaction studies have been performed yet.

References

  1. ^ DiDomenico RJ, Walton SM, Sanoski CA, Bauman JL (2000). "Analysis of the use of digoxin immune fab for the treatment of non-life-threatening digoxin toxicity". J. Cardiovasc. Pharmacol. Ther. 5 (2): 77–85. doi:10.1053/XV.2000.5590. PMID 11150387.
  2. ^ http://reference.medscape.com/drug/digibind-digifab-digoxin-immune-fab-antidote-343725
  3. ^ http://lifeinthefastlane.com/ccc/digoxin-toxicity/

External links